C
Caldera Therapeutics
Clinical-stage bispecific antibody for inflammatory bowel disease
About Caldera Therapeutics
Caldera Therapeutics is a clinical-stage biotechnology company founded in 2025 and based in Cambridge, Massachusetts. The company launched publicly in January 2026 with $112.5 million in total capital raised. This funding consisted of a $75 million Series A round from founding investors Atlas Venture, LAV, and venBio, followed by a $37.5 million Series A-1 round led by Omega Funds with participation from Wellington Management and Janus Henderson Investors.
Read full description
Caldera is focused on developing treatments for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases. The company's business model centers on advancing its lead program, CLD-423, a first-in-class bispecific antibody. Caldera believes that therapies targeting a single pathway have reached an efficacy ceiling in IBD and that a dual-pathway approach may yield better outcomes. CLD-423 simultaneously targets two clinically validated pathways, IL-23p19 and TL1A, which have been implicated in IBD. The company in-licensed the exclusive global development and commercialization rights for CLD-423 from China's Qyuns Therapeutics.
The leadership team includes CEO Praveen Tipirneni, former CEO of Morphic Therapeutic, and Chief Scientific Officer Liangsu Wang, who also held a leadership role at Morphic Therapeutic. The team has significant experience in IBD drug discovery and development. As of its public launch in January 2026, Caldera had already initiated a Phase 1 clinical trial of CLD-423 in healthy volunteers.
At a glance
- Status
- Operational
- Headquarters
- Cambridge, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Drug Development, Inflammatory Diseases, Immune System
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Jul 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Latest news
Press, funding announcements and product moves mentioning Caldera Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| IPOOther financing | Jul 2026 | $0 | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT NON VCOther financing | Jul 2026 | $278M | — | Atlas Venture · venBio Partners · Janus Henderson Investors · TCGX | ↗ |
Growth signals
Latest recorded traffic for Caldera Therapeutics is 4.2K monthly website visits, up 475.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 RespiradigmNature-derived, non-steroidal therapeutics for adult asthma. |
Perth, Australia | Operational | 2 | — | — |
 Khartis TherapeuticsOral small molecule therapies for immunological diseases. |
San Diego, United States | Operational | |||
 QUASAR TherapeuticsEngineered protein regulators for complement-mediated diseases. |
Ulm, Germany | Operational | |||
 MirageneAdvanced biologics for immunological and inflammatory diseases. |
San Diego, United States | Operational | |||
 Baerenkraft TherapeuticsBiotech & Life Sciences |
Lehi, United States | Operational | |||
 Khanda TherapeuticsBiotech company builder translating biology into therapeutics. |
London, United Kingdom | Operational | |||
 Talawar TherapeuticsBispecific antibodies for immunology and inflammatory diseases. |
Boston, United States | Operational | |||
 ProteologixBispecific antibody therapeutics for immune-mediated diseases. |
San Carlos, United States | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Atlas Venture
venBio Partners- LALAV
Omega Funds
Janus Henderson Investors
Wellington Management
Other known investors5 additional known investors
Bain Capital Life Sciences
Blackstone
Sirenia Capital Management
TCGX
Vivo Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Caldera Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Caldera Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.